Clinical trial investigates Alzheimer's disease drug in people with Down syndrome

May 31, 2017, Massachusetts General Hospital

A phase 2 clinical trial in young adults with Down syndrome of a drug being investigated for the treatment of Alzheimer's disease supports further investigation of its potential. Results of the four-week trial of scyllo-inositol, also known as ELND005, have been published in the Journal of Alzheimer's Disease.

"Through this study, members of the Down community have demonstrated loudly and clearly that they are eager to participate in , particularly studies that provide promise for the treatment of Alzheimer's disease," says Brian Skotko, MD, MPP, co-director of the Massachusetts General Hospital (MGH) Down Syndrome Program, and a site principal investigator for the trial. "This first, industry-sponsored phase 2 trial in the Down syndrome community showed that people with Down syndrome were able to follow the study protocol and that the drug was safe and tolerable."

The most common form of intellectual disability in the United States, Down syndrome is caused by an extra copy of chromosome 21. People with Down syndrome exhibit various degrees of and are at greatly increased risk of developing Alzheimer's dementia as they age. Excess activity of the genes on chromosome 21 - including the gene for the , the source of found in the brains of people with Alzheimer's disease - is thought to play a role in the cognitive challenges of people with Down syndrome.

Another chromosome 21 gene believed to play a role in Down syndrome contributes to the metabolism of myo-inositol, a signaling molecule increased in the brains of children and adults with Down syndrome at levels that correlate to the severity of symptoms. Lifelong exposure to increased levels of both amyloid and myo-inositol are believed to contribute to brain dysfunction and cognitive disability. Scyllo-inositol may have potential to improve cognition in patients with Down syndrome both by decreasing amyloid levels and regulating myo-inositol-dependent signaling in the brain.

The clinical trial enrolled 23 adults with Down syndrome, ages 18 to 45, who were randomized to receive one of two dosages of scyllo-inositol - 250 mg either daily or twice a day - or a placebo. All but one participant completed the four-week trial with no significant deviations from the protocol. There were no serious adverse events and no changes in vital signs, laboratory tests or other physical findings. While treatment produced no apparent cognitive or behavioral changes, the duration of the trial was too short to capture such effects.

"Scyllo-inositol has been extensively tested in the typical Alzheimer's disease population, but this study looked at it specifically in people with Down syndrome who are at an for AD," says Michael Rafii, MD, PhD, clinical director of the Alzheimer's Therapeutic Research Institute at the University of Southern California and associate professor in the Department of Neuroscience at the University of California, San Diego, lead and corresponding author of the study. "The results of this study are encouraging, and further study of this compound in Down syndrome should certainly be considered."

Explore further: Down syndrome research untangles therapeutic possibilities for Alzheimer's

More information: Michael S. Rafii et al, A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia, Journal of Alzheimer's Disease (2017). DOI: 10.3233/JAD-160965

Related Stories

Down syndrome research untangles therapeutic possibilities for Alzheimer's

September 17, 2015
More than five million Americans are living with Alzheimer's disease (AD). Of them, 400,000 also have Down syndrome. Both groups have similar looking brains with higher levels of the protein beta amyloid. In fact, patients ...

Researchers use imaging technique to predict dementia status in adults with down syndrome

August 10, 2016
Researchers at the University of Kentucky Sanders-Brown Center on Aging found that magnetic resonance spectroscopy (MRS), a noninvasive imaging technique, might help distinguish between people with Down syndrome who have ...

Down syndrome helps researchers understand Alzheimer's disease

September 18, 2014
The link between a protein typically associated with Alzheimer's disease and its impact on memory and cognition may not be as clear as once thought, according to a new study from the University of Wisconsin-Madison's Waisman ...

Studying Down syndrome might help us understand Alzheimer's disease better

May 5, 2015
Alzheimer's disease is the most common form of dementia in older adults. At the moment there is no cure, but many clinicians feel that the earlier one is diagnosed, the better the possibilities are for treatment or slowing ...

Study reveals new link between Down syndrome and Alzheimer's

November 2, 2015
Individuals with Down syndrome who survive into adulthood face the additional challenge of early-onset dementia, in which toxic amyloid plaques build up in the brain. The condition is strikingly similar to Alzheimer's disease, ...

Brain imaging changes in individuals with Down's may help advance Alzheimer's trials

April 14, 2015
Researchers have characterized three different brain imaging changes in individuals with Down syndrome, who are at very high risk for development of Alzheimer's disease, even before the onset of progressive memory and thinking ...

Recommended for you

New study suggests viral connection to Alzheimer's disease

June 21, 2018
Of the major illnesses facing humanity, Alzheimer's disease (AD) remains among the most pitiless and confounding. Over a century after its discovery, no effective prevention or treatment exists for this progressive deterioration ...

New screening tool could help diagnose early cognitive decline in dementia from home

June 19, 2018
An international team of scientists have developed a new way to screen for age-related cognitive decline at home using a test which asks people to detect sounds and flashes on their laptop or phone.

Genes linked to Alzheimer's contribute to damage in different ways

June 12, 2018
Multiple genes are implicated in Alzheimer's disease. Some are linked to early-onset Alzheimer's, a condition that develops in one's 30s, 40s and 50s, while others are associated with the more common late-onset form of the ...

Researchers reverse cognitive impairments in mice with dementia

June 8, 2018
Reversing memory deficits and impairments in spatial learning is a major goal in the field of dementia research. A lack of knowledge about cellular pathways critical to the development of dementia, however, has stood in the ...

As mystery deepens over the cause of Alzheimer's, researchers seek new answers

June 6, 2018
For more than 20 years, much of the leading research on Alzheimer's disease has been guided by the "amyloid hypothesis."

Research reveals how Tau aggregates can contribute to cell death in Alzheimer's disease

June 5, 2018
New evidence suggests a mechanism by which progressive accumulation of Tau protein in brain cells may lead to Alzheimer's disease. Scientists studied more than 600 human brains and fruit fly models of Alzheimer's disease ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.